Business Insight: cell & gene therapy

Published: 1 February 2021
Expert Insight
Jackie Mulryne,
Jackie Mulryne
Partner, Arnold & Porter
Jackie Mulryne is a Partner at Arnold & Porter, focusing on regulatory and contentious matters for life sciences companies. She has advised a range of clients on the development and launch of innovative products, and assisted with navigating the regulatory landscape for novel cell and gene therapy products.
Dr Beatriz San Martin,
Dr Beatriz San Martin
Partner, Arnold & Porter
Beatriz San Martin is an intellectual property specialist focusing her practice on the life sciences sector and emerging/disruptive technologies. She has significant experience handling cases before the UK Courts and the Court of Justice of the European Union, including high-profile European litigation. Beatriz was formerly a scientist with a Wellcome Trust PhD and a postdoctoral from the University of Cambridge specializing in genetics, cellular, and molecular biology. She is a member of the UK BioIndustry Association Cell and Gene Therapy Advisory Committee and Engineering Biology Advisory Committee.
John Schmidt,
John Schmidt
Partner, Arnold & Porter
Ewan Townsend
Ewan Townsend
Partner, Arnold & Porter

European legal issues stemming from the COVID-19 pandemic: regulatory, intellectual property, contract and competition law relevant to cell and gene therapy products

Read now